Metformin and Angiogenesis in Cancer - Revisited

Area of Science:

• Pharmacology
• Oncology
• Vascular Biology

Background:

• Metformin use in diabetic patients is linked to reduced vascular complications, irrespective of blood sugar levels.
• Metformin's vascular benefits extend to non-diabetic conditions, suggesting broader therapeutic applications.
• Tumor angiogenesis is a critical process in cancer development and progression.

Purpose of the Study:

• To review the literature on metformin's role in tumor angiogenesis.
• To explore metformin's potential in treating vascular dysfunction and cancer.
• To suggest future research and clinical strategies for metformin in oncology.

Main Methods:

• Literature review of existing clinical and experimental studies.
• Analysis of metformin's mechanisms of action on vascular and tumor biology.
• Synthesis of data on metformin's efficacy as a single agent versus combination therapy.

Main Results:

• Metformin exhibits diverse vascular actions applicable to non-diabetic states.
• Metformin as a standalone antiangiogenic agent in cancer has shown limited success.
• Normalization of tumor vasculature is a promising strategy for improving drug delivery.

Conclusions:

• Metformin holds potential for treating vascular dysfunction and tumor angiogenesis beyond diabetes.
• Combination therapy involving metformin may represent a viable strategy to enhance conventional cancer treatments.
• Further experimental and clinical investigations are warranted to optimize metformin's use in oncology.